Evidence map›Paper›PMID 40012790›Full record

ArticleFrontiers in microbiology2025

Does viral circulation in slums have a global impact? The lesson learned from SARS-CoV-2 circulation in

Monique Cristina Dos Santos, Natalia Fintelman-Rodrigues, Aline de Paula Dias da Silva, Rodolfo Leandro Nascimento Silva, Victor Corrêa Seixas, Amanda A Batista-da-Silva, Marcelo Alves Ferreira, Patrícia T Bozza, Fernando A Bozza, Thiago Moreno L Souza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Monique Cristina Dos SantosLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.
Natalia Fintelman-RodriguesLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.
Aline de Paula Dias da SilvaLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.
Rodolfo Leandro Nascimento SilvaInstituto de Biologia, Universidade Federal Fluminense (UFF), Rio de Janeiro, Brazil.
Victor Corrêa SeixasInstituto de Biologia, Universidade Federal Fluminense (UFF), Rio de Janeiro, Brazil.
Amanda A Batista-da-SilvaInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil.
Marcelo Alves FerreiraNational Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Brazil.
Patrícia T BozzaLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.
Fernando A BozzaInstituto de Biologia, Universidade Federal Fluminense (UFF), Rio de Janeiro, Brazil.
Thiago Moreno L SouzaLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because of growing inequalities, more than one-third of the worldwide population is expected to live in slums by 2050. Although slum dwellers are at increased risk of infectious diseases, this population may have been overlooked with respect to the sustainability of virus evolution. In this study, we aimed to analyze the genetic diversity and evolution of SARS-CoV-2 in the

Indexed as

BrazilCOVID-19Rio de JaneiroSARS-CoV-2slum

Identifiers

PMID40012790
PMCPMC11861056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.